Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases.

The recent landmark Phase III clinical trial with a VEGF-specific antibody suggests that antiangiogenic therapy must be combined with cytotoxic therapy for the treatment of solid tumors. However, there are no guidelines for optimal scheduling of these therapies. Here we show that VEGFR2 blockade creates a "normalization window"--a period during which combined radiation therapy gives the best outcome. This window is characterized by an increase in tumor oxygenation, which is known to enhance radiation response. During the normalization window, but not before or after it, VEGFR2 blockade increases pericyte coverage of brain tumor vessels via upregulation of Ang1 and degrades their pathologically thick basement membrane via MMP activation.

[1]  E. Tsilibary.  Microvascular basement membranes in diabetes mellitus , 2003, The Journal of pathology.

[2]  Rakesh K Jain,et al.  Molecular regulation of vessel maturation , 2003, Nature Medicine.

[3]  Hyun Seok Song,et al.  SSeCKS regulates angiogenesis and tight junction formation in blood-brain barrier , 2003, Nature Medicine.

[4]  P. Carmeliet,et al.  Vascular endothelial growth factor (VEGF)-C differentially affects tumor vascular function and leukocyte recruitment: role of VEGF-receptor 2 and host VEGF-A. , 2001, Cancer research.

[5]  Lance A. Liotta,et al.  Cancer: Out of air is not out of action , 2003, Nature.

[6]  Patrick England,et al.  A short synthetic peptide inhibits signal transduction, migration and angiogenesis mediated by Tie2 receptor , 2004, EMBO reports.

[7]  Rakesh K. Jain,et al.  Vascular Normalization by Vascular Endothelial Growth Factor Receptor 2 Blockade Induces a Pressure Gradient Across the Vasculature and Improves Drug Penetration in Tumors , 2004, Cancer Research.

[8]  P. Carmeliet,et al.  Angiogenesis in cancer and other diseases , 2000, Nature.

[9]  J M Gallo,et al.  Pharmacodynamic-mediated reduction of temozolomide tumor concentrations by the angiogenesis inhibitor TNP-470. , 2001, Cancer research.

[10]  Hyun Seok Song,et al.  Oxygen tension regulates the maturation of the blood-brain barrier. , 2002, Biochemical and biophysical research communications.

[11]  M. Skobe,et al.  Activation of the tie2 receptor by angiopoietin-1 enhances tumor vessel maturation and impairs squamous cell carcinoma growth. , 2002, The American journal of pathology.

[12]  G. Koh,et al.  Angiopoietin-1 inhibits irradiation- and mannitol-induced apoptosis in endothelial cells. , 2000, Circulation.

[13]  C. Dinney,et al.  Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[14]  N. Glazer,et al.  Angiopoietin-1 protects the adult vasculature against plasma leakage , 2000, Nature Medicine.

[15]  A. Ullrich,et al.  Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant , 1994, Nature.

[16]  R. Kallman,et al.  Oxygen effect and reoxygenation , 1975 .

[17]  H. Dvorak.  Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  R. Weichselbaum,et al.  Combined effects of angiostatin and ionizing radiation in antitumour therapy , 1998, Nature.

[19]  L. Ellis,et al.  Angiopoietin-1 inhibits vascular permeability, angiogenesis, and growth of hepatic colon cancer tumors. , 2003, Cancer research.

[20]  G. Yancopoulos,et al.  Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. , 1999, Science.

[21]  E. Hall,et al.  Radiobiology for the radiologist , 1973 .

[22]  Mechthild Krause,et al.  Experimental study on different combination schedules of VEGF-receptor inhibitor PTK787/ZK222584 and fractionated irradiation. , 2003, Anticancer research.

[23]  R. Jain,et al.  Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. , 2001, Cancer research.

[24]  M Ancukiewicz,et al.  Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. , 2000, Cancer research.

[25]  M. Shibuya,et al.  MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. , 2002, Cancer cell.

[26]  R K Jain,et al.  Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[27]  P. Workman,et al.  Direct measurement of pO2 distribution and bioreductive enzymes in human malignant brain tumors. , 1994, International journal of radiation oncology, biology, physics.

[28]  Georg Breier,et al.  Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo , 1992, Nature.

[29]  Gavin Thurston,et al.  Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. , 2004, The American journal of pathology.

[30]  D. McDonald,et al.  Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors. , 2003, The American journal of pathology.

[31]  J. Folkman,et al.  Clinical translation of angiogenesis inhibitors , 2002, Nature Reviews Cancer.

[32]  R. Jain,et al.  Leaky vessels? Call Ang1! , 2000, Nature Medicine.

[33]  R. Vos,et al.  Pathological features of cerebral cortical capillaries are doubled in Alzheimer’s disease and Parkinson’s disease , 2000, Acta Neuropathologica.

[34]  Kenneth J. Hillan,et al.  Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer , 2004, Nature Reviews Drug Discovery.

[35]  E. Rofstad,et al.  Antiangiogenic treatment with thrombospondin-1 enhances primary tumor radiation response and prevents growth of dormant pulmonary micrometastases after curative radiation therapy in human melanoma xenografts. , 2003, Cancer research.

[36]  K. Plate,et al.  Cell type-specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis. , 1998, The American journal of pathology.

[37]  R. Weichselbaum,et al.  Potentiation of the antitumor effect of ionizing radiation by brief concomitant exposures to angiostatin. , 1998, Cancer research.

[38]  T. Suda,et al.  Expression of angiopoietin-2 in human glioma cells and its role for angiogenesis. , 2001, Cancer research.

[39]  Ricky T. Tong,et al.  Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer , 2004, Nature Medicine.

[40]  Y. Kakeji,et al.  Influence of an anti‐angiogenic treatment on 9L gliosarcoma: Oxygenation and response to cytotoxic therapy , 1995, International journal of cancer.

[41]  Zvi Fuks,et al.  Tumor Response to Radiotherapy Regulated by Endothelial Cell Apoptosis , 2003, Science.

[42]  R K Jain,et al.  Vascular permeability and microcirculation of gliomas and mammary carcinomas transplanted in rat and mouse cranial windows. , 1994, Cancer research.

[43]  Thomas N. Sato,et al.  Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. , 1999, Science.

[44]  R. Kammerer,et al.  Designed angiopoietin-1 variant, COMP-Ang1, protects against radiation-induced endothelial cell apoptosis. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[45]  Rakesh K. Jain,et al.  Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy , 2001, Nature Medicine.

[46]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[47]  D. Pode,et al.  Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. , 1999, The Journal of clinical investigation.

[48]  Akiyoshi Uemura,et al.  Recombinant angiopoietin-1 restores higher-order architecture of growing blood vessels in mice in the absence of mural cells. , 2002, The Journal of clinical investigation.

[49]  M Hiraoka,et al.  An antiangiogenic agent (TNP-470) inhibited reoxygenation during fractionated radiotherapy of murine mammary carcinoma. , 1997, International journal of radiation oncology, biology, physics.

[50]  A. Dicker,et al.  Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.